

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934.**

**Date of Report: May 9, 2008  
(Date of earliest event reported)**

---

**Oragenics, Inc**

(Exact name of registrant as specified in its charter)

---

**FL**  
(State or other jurisdiction  
of incorporation)

**001-38122**  
(Commission File Number)

**59-3410522**  
(IRS Employer  
Identification Number)

**13700 Progress Blvd**  
(Address of principal executive offices)

**32615**  
(Zip Code)

**386-418-4018**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 OTHER EVENTS**

On May 9, 2008, Oragenics, Inc. (the "Company") issued a press release regarding the expected test marketing of its oral probiotic product, Probiora3 to consumers to improve breath and whiten teeth. The press release is attached to this report as Exhibit 99.1 and incorporated by reference herein.

---

**Item 9.01 FINANCIAL INFORMATION AND EXHIBITS****(c) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated May 9, 2008

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 9<sup>th</sup> day of May, 2008.

**ORAGENICS, INC.**  
**(Registrant)**

BY: /s/ Stanley Stein

Stanley Stein  
President and Chief Executive Officer

**Oragenics Announces Test Marketing of Probiora3™ Chewable Tablets****FOR IMMEDIATE RELEASE**

**ALACHUA, FL (May 9, 2008)** – Oragenics, Inc. (AMEX:ONI) announced today the test marketing of its oral probiotic product, Probiora3. The chewable tablets help to whiten teeth and improve breath through the use of a unique combination of safe, naturally occurring bacteria that are released in the mouth by chewing on a mint-flavored tablet that the Company has designed to be used twice daily.

The Company believes that further analysis and possible further testing of the product will show that Probiora3 will also improve oral health for those millions of people who suffer from chronic tooth and gum problems, although no such representations can be made at this time. Probiora3 is the first of the Company's many products to be brought to market.

The Company expects to begin direct-to-consumer sales within the next month through a subsidiary company and to bring the product to the public's attention through the media.

Rick Welch, Chairman of Oragenics' Board, stated, "I am enthusiastic about the current and potential consumer benefits of Probiora3, and recognize that it marks the first of what we hope are a long line of pharma and non-pharma products to reach market in time to come."

Dr. Jeffrey D. Hillman, Oragenics' Chief Scientific Officer, added, "Probiora3 is a blend of three naturally occurring and beneficial oral bacteria. The chewable tablet is the first of our planned products for diagnosing and treating a number of infectious diseases including those that affect the mouth."

**About Oragenics**

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

*Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

---

*Contact:*

Orogenics, Inc.  
Stanley B. Stein, 386-418-4018 X222  
[www.rogenics.com](http://www.rogenics.com)

###